{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00544:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00544%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004788,
    "timestamp_received": "2026-05-06T15:49:14.954561+00:00Z",
    "timestamp_returned": "2026-05-06T15:49:14.959349+00:00Z",
    "trace_id": "ca29c34b-e899-4900-bcb7-83e82a2d1588"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-27"
  },
  "data": [
    {
      "id": "ind:hse.00544:a",
      "indication": "Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.",
      "initial_approval_date": "2019-03-01",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
      "raw_biomarkers": "EGFR mutations or ALK fusion",
      "raw_cancer_type": "Non-small cell lung cancer",
      "raw_therapeutics": "Tecentriq (atezolizumab)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00544",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Atezolizumab Monotherapy, 2025, version number 14, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6644/544_v14_Atezolizumab_21_Day_Monotherapy.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6644/544_v14_Atezolizumab_21_Day_Monotherapy.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-06-14",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}